M

ore than 150 biotech executives and investors took a stand against President Donald Trump’s immigration ban, saying the controversial executive order threatens to undermine a multibillion-dollar industry that relies on a diverse workforce.

Trump’s order — currently suspended while a federal appeals court weighs its merits — barred nationals from seven Muslim-majority nations from entering the US, regardless of their legal status. For biotech, an industry that relies heavily on foreign-born workers, the ban is particularly ominous, executives wrote in a letter to Nature Biotechnology.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What you really mean is: controversial executive order threatens to undermine a multibillion-dollar industry that relies on a cheap foreign workforce.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy